Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer

Cao, Liyun; Lee, Chi Hyun; Ning, Jing; Handy, Beverly Carol; Wagar, Elizabeth A.; Meng, Qing H.

doi:10.5858/arpa.2017-0185-oa

Cited by 14 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent data also revealed that a logistic regression algorithm combining PCA3 with PSA significantly increased PCa diagnostic properties [65]. This combined evaluation was able to discriminate low-grade from high-grade cancers.…”

Section: Pca3 As a Biomarkermentioning

confidence: 96%

“…In an attempt to improve PCa diagnosis, some studies have demonstrated better results of PCA3 in association with PSA [64, 65], in addition to prostate-specific G-protein coupled receptor (PSGR) [66], a biomarker previously described to be overexpressed in PCa tissue [67]. Other authors found that the combination of PCA3 , PSA, and human kallikrein 2 (hK2) largely improved area under the curve (AUC)-receiver operating characteristic (ROC), especially those patients presenting PSA 4-10 ng/mL [64].…”

Section: Pca3 As a Biomarkermentioning

confidence: 99%

See 1 more Smart Citation

The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer

et al. 2019

View full text Add to dashboard Cite

Prostate cancer antigen 3 (PCA3) is an overexpressed prostate long non-coding RNA (lncRNA), transcribed from an intronic region at the long arm of human chromosome 9q21–22. It has been described that PCA3 modulates prostate cancer (PCa) cell survival through modulating androgen receptor (AR) signaling, besides controlling the expression of several androgen responsive and cancer-related genes, including epithelial–mesenchymal transition (EMT) markers and those regulating gene expression and cell signaling. Also, PCA3 urine levels have been successfully used as a PCa diagnostic biomarker. In this review, we have highlighted recent findings regarding PCA3, addressing its gene structure, putative applications as a biomarker, a proposed origin of this lncRNA, roles in PCa biology and expression patterns. We also updated data regarding PCA3 interactions with cancer-related miRNAs and expression in other tissues and diseases beyond the prostate. Altogether, literature data indicate aberrant expression and dysregulated activity of PCA3, suggesting PCA3 as a promising relevant target that should be even further evaluated on its applicability for PCa detection and management.

show abstract

Section: Pca3 As a Biomarkermentioning

confidence: 96%

Section: Pca3 As a Biomarkermentioning

confidence: 99%

The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…3,4 Phylloides tumour of the vulva is an extremely rare entity, and the least common of the differentials for non-acute labial masses. 5 It most likely occurs in ectopic breast tissue anywhere along the primitive embryonic milk line extending from the axilla to the groin bilaterally, as a result of failure of mammary ridges to regress. 6 This embryonic milk line can be the site of similar pathological lesions seen in the normal breast.…”

Section: Discussionmentioning

confidence: 99%

A rare case of genital labial phylloides tumour

2020

View full text Add to dashboard Cite

“…Previous studies 19 have shown that detecting patients’ urine PCA3 using RT-PCR can help avoid unnecessary biopsies. Additionally, a study 20 showed that the combination of PCA3 and TMPRSS2: ERG or PCA3 and PSA 21 can improve the detecting rate of PCa. Notably, there are studies 22,23 claiming that the diagnostic efficacy of PCA3 could be significantly different in different populations.…”

Section: Discussionmentioning

confidence: 99%

Prostate Cancer Diagnosis Using Urine Sediment Analysis-Based α-Methylacyl-CoA Racemase Score: A Single-Center Experience

Chen

et al. 2019

Cancer Control

View full text Add to dashboard Cite

To evaluate the diagnostic value of α-methylacyl-CoA racemase (AMACR) score in Han Chinese patients with prostate cancer (PCa) through urine sediment analysis. We collected 292 urine sediment samples after digital rectal examination. Levels of AMACR and prostate-specific antigen (PSA) messenger RNA (mRNAs) were evaluated by quantitative real time-polymerase chain reaction. The diagnostic value of AMACR score was assessed by receiver-operating characteristic analysis (ROC), Mann-Whitney test, logistic regression analysis and decision curve analysis. In all patients (n = 292), the area under the curve (AUC) for serum PSA, AMACR score, and a combinative model of these 2 parameters were 0.745 (95% confidence interval [CI]: 0.691-0.794), 0.753 (95% CI: 0.700-0.802), and 0.784 (95% CI: 0.732-0.830). No statistical difference was found between AMACR score and serum PSA (P = .826), while the combinative model was better than AMACR score (Z = 5.222, P < .001). Among patients with serum PSA level of 4 to 10 ng/mL (n = 121), the AMACR score was significantly higher in patients with PCa (P = 0.0002), while serum PSA showed no difference (P = 0.3023). Alpha-methylacyl-CoA racemase score (AUC = 0.712, 95% CI: 0.623-0.790) and a combinative model (AUC = 0.714, 95% CI: 0.626-0.793) showed a better diagnostic value than serum PSA (AUC = 0.559, 95% CI: 0.466-0.649), (P = .048, P = .042). Decision curve analysis showed a biopsy prediction model including AMACR score have a better net benefit when the threshold probability greater than 20%. The diagnostic model combing serum PSA and AMACR score has a better diagnostic value in patients with abnormal PSA level (including PSA level ranging from 4-10 ng/mL), and could reduce unnecessary prostate biopsy in clinical use.

show abstract

Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer

Abstract: - Our data suggest that PCA3 improves the diagnostic sensitivity and specificity of PSA and that the combination of PCA3 with PSA gives better overall performance in identification of PCa than serum PSA alone in the high-risk population.

Cited by 14 publications

References 34 publications

The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer

The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer

A rare case of genital labial phylloides tumour

Prostate Cancer Diagnosis Using Urine Sediment Analysis-Based α-Methylacyl-CoA Racemase Score: A Single-Center Experience

Contact Info

Product

Resources

About